Aducanumab  (Synonyms: BIIB037)

Aducanumab (BIIB037) is a human monoclonal antibody that selectively targets aggregated amyloid-beta (Aβ). Aducanumab shows blood-brain-barrier penetration, and can be used for Alzheimer's disease (AD) research^[1].

Human IgG1 kappa

Human IgG1 kappa, Isotype Control

Human

Amyloid Beta/Aβ

Aducanumab (30 mg/kg, i.p., single dose) binds all morphological types of brain Aβ plaques in 22-month-old Tg2576 transgenic mice, including diffuse Aβ deposits and compact Aβ plaques^[1].
Aducanumab (0.3-30 mg/kg, i.p., weekly, 6 months) reduces soluble and insoluble Aβ in a dose-dependent manner in 9.5- to 15.5-month-old Tg2576 transgenic mice^[1].
Aducanumab (10 mg/kg, i.p., weekly, 6 months) restores intracellular calcium to control levels in 18-month-old Tg2576 mice^[2].
Aducanumab (0.4-1 mg/mL, ICV, 20 min) leads to rapid decrease in amyloid burden, plaque clearance in Tg2576 mice^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

351  [NCBI]

P05067

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

146.2 kDa

1384260-65-4

Liquid

Colorless to light yellow

[Aducanumab]

Shipping with dry ice.

Please refer to the lot-specific COA for specific buffer information.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Human IgG1 kappa

• 
  Immobilized Human Beta-amyloid/Beta-APP Protein (hFc Tag) can bind Aducanumab. The EC₅₀ for this effect is 603.66 ng/mL.
• 
  The EC₅₀ for this effect is 603.66 ng/mL. Flow cytometric analysis of 1.5×10⁶ HUVEC cells with Aducanumab (HY-P9967, red). Cells were fixed with 4% paraformaldehyde and permeabilised with 90% methanol. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. Goat Anti-Human IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG1 kappa, Isotype Control (HY-P99001, blue) was used as the isotype control.

• [1]. Sevigny J, et al. The antibody aducanumab reduces Aβ plaques in Alzheimer's disease. Nature. 2016 Sep 1;537(7618):50-6.  [Content Brief]

  [2]. Kastanenka KV, et al. Immunotherapy with Aducanumab Restores Calcium Homeostasis in Tg2576 Mice. J Neurosci. 2016 Dec 14;36(50):12549-12558.  [Content Brief]